Details for: SF3B2
Gene ID: 10992
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: SF3B2
Ensembl ID: ENSG00000087365
Description: splicing factor 3b subunit 2
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 65.53rCSI 59.18%PRS 6.67
-
CSI 57.2rCSI 46.25%PRS 7.43
-
CSI 57.05rCSI 44.88%PRS 9.01
-
CSI 50.01rCSI 43.31%PRS 8.4
-
CSI 46.81rCSI 46.72%PRS 6.47
-
CSI 46.37rCSI 44.64%PRS 7.81
-
CSI 45.14rCSI 30%PRS 9
-
CSI 43.19rCSI 37.98%PRS 5.46
-
CSI 42.71rCSI 49.39%PRS 5.52
-
CSI 42.59rCSI 32.81%PRS 6.83
-
CSI 36.91rCSI 42.25%PRS 15.68
-
CSI 36.71rCSI 46.07%PRS 9.61
-
CSI 33.58rCSI 41.55%PRS 6.62
-
CSI 30.91rCSI 52.95%PRS 10.12
-
CSI 29.49rCSI 29.01%PRS 8.19
-
CSI 28.36rCSI 28.91%PRS 10.86
-
CSI 26.5rCSI 38.22%PRS 10.53
-
CSI 26.39rCSI 75.33%PRS 13.42
-
CSI 23.78rCSI 47.4%PRS 12.87
-
CSI 21.74rCSI 29.05%PRS 14.43
-
CSI 20.74rCSI 18.22%PRS 8.47
-
CSI 19.92rCSI 26.48%PRS 8.2
-
CSI 19.13rCSI 12.89%PRS 9.1
-
CSI 18.37rCSI 19.24%PRS 8.03
-
CSI 18.32rCSI 21.51%PRS 9.03
-
CSI 18.11rCSI 52.44%PRS 8.56
-
CSI 17.31rCSI 26.75%PRS 7.09
-
CSI 16.27rCSI 17.43%PRS 6.93
-
CSI 15.78rCSI 10.52%PRS 20.78
-
CSI 15.4rCSI 12.76%PRS 7.57
-
CSI 14.22rCSI 13.71%PRS 4.74
-
CSI 14.18rCSI 11.89%PRS 9.03
-
CSI 14.1rCSI 14.74%PRS 7.94
-
CSI 12.92rCSI 25.13%PRS 7.68
-
CSI 12.43rCSI 48.37%PRS 12.46
-
CSI 12.37rCSI 28.19%PRS 7.89
-
CSI 11.6rCSI 40.69%PRS 13.73
-
CSI 11.49rCSI 75.39%PRS 20
-
CSI 11.13rCSI 16.44%PRS 11.93
-
CSI 11.11rCSI 15.19%PRS 12.86
-
CSI 10.82rCSI 16.56%PRS 12.32
-
CSI 10.61rCSI 42.21%PRS 13.38
-
CSI 10.29rCSI 36.57%PRS 24.34
-
CSI 9.7rCSI 10.91%PRS 12.38
-
CSI 9.69rCSI 31.1%PRS 11.27
-
CSI 9.66rCSI 49.9%PRS 15.17
-
CSI 9.62rCSI 51.93%PRS 14.52
-
CSI 9.59rCSI 14.03%PRS 7.99
-
CSI 9.53rCSI 58.87%PRS 24.97
-
CSI 9.46rCSI 27.92%PRS 9.46
-
CSI 8.84rCSI 6.17%PRS 7.95
-
CSI 8.84rCSI 51.42%PRS 11.39
-
CSI 8.81rCSI 7.3%PRS 7.16
-
CSI 8.49rCSI 45.28%PRS 27.87
-
CSI 8.42rCSI 25.12%PRS 19.74
-
CSI 8.22rCSI 12.54%PRS 7.09
-
CSI 8.11rCSI 10.09%PRS 8.05
-
CSI 7.94rCSI 12.86%PRS 7.69
-
CSI 7.87rCSI 8.24%PRS 7.02
-
CSI 7.81rCSI 13.8%PRS 4.43
-
CSI 6.96rCSI 4.84%PRS 8.83
-
CSI 6.87rCSI 24.38%PRS 12.42
-
CSI 6.86rCSI 15.19%PRS 7
-
CSI 6.81rCSI 23.04%PRS 12.93
-
CSI 6.72rCSI 4.83%PRS 10.27
-
CSI 6.58rCSI 15.65%PRS 11.36
-
CSI 6.35rCSI 7.62%PRS 7.47
-
CSI 6.08rCSI 4.91%PRS 15
-
CSI 5.8rCSI 7.9%PRS 6.76
-
CSI 5.79rCSI 5.03%PRS 9.32
-
CSI 5.72rCSI 5.01%PRS 10.17
-
CSI 5.66rCSI 8.3%PRS 8.85
-
CSI 5.46rCSI 4.13%PRS 10.52
-
CSI 5.44rCSI 3.82%PRS 21.46
-
CSI 5.42rCSI 14.89%PRS 12.52
-
CSI 5.3rCSI 6.94%PRS 37.5
-
CSI 5.3rCSI 3.97%PRS 22.25
-
CSI 5.12rCSI 22.5%PRS 14.21
-
CSI 5.1rCSI 6.52%PRS 33.56
-
CSI 5.03rCSI 13.56%PRS 9.77
-
CSI 4.9rCSI 4.53%PRS 13.86
-
CSI 4.83rCSI 10.28%PRS 13.98
-
CSI 4.83rCSI 3.93%PRS 8.03
-
CSI 4.81rCSI 33.96%PRS 24.08
-
CSI 4.77rCSI 21.18%PRS 7.55
-
CSI 4.52rCSI 4.21%PRS 7.59
-
CSI 4.49rCSI 3.55%PRS 5.2
-
CSI 4.41rCSI 4.06%PRS 7.68
-
CSI 4.39rCSI 64.93%PRS 20.29
-
CSI 4.39rCSI 10.53%PRS 14.05
-
CSI 4.37rCSI 3.75%PRS 16.49
-
CSI 4.34rCSI 3.85%PRS 7.54
-
CSI 4.31rCSI 23.48%PRS 19.18
-
CSI 4.19rCSI 20.65%PRS 10.21
-
CSI 4.17rCSI 76.2%PRS 21.53
-
CSI 4.07rCSI 5.8%PRS 8.52
-
CSI 4.06rCSI 6.03%PRS 9.46
-
CSI 4.04rCSI 6.21%PRS 10.83
-
CSI 4.01rCSI 2.97%PRS 6.87
-
CSI 3.9rCSI 23.6%PRS 17.49
-
CSI -7.4rCSI -13.5%PRS 6.6%
-
CSI -6.9rCSI -30.2%PRS 7.6%
-
CSI -5.8rCSI -35.9%PRS 6.2%
-
CSI -4.9rCSI -8.7%PRS 10.0%
-
CSI -4.5rCSI -9.4%PRS 7.5%
-
CSI -3.0rCSI -9.7%PRS 5.5%
-
CSI -2.6rCSI -6.0%PRS 17.5%
-
CSI -2.1rCSI -3.7%PRS 5.8%
-
CSI -1.5rCSI -6.8%PRS 25.0%
-
CSI -1.2rCSI -3.1%PRS 10.6%
-
CSI -1.1rCSI -2.0%PRS 9.1%
-
CSI -1.1rCSI -3.2%PRS 14.1%
-
CSI -1.1rCSI -1.4%PRS 10.1%
-
CSI -1.0rCSI -5.8%PRS 10.8%
-
CSI -1.0rCSI -5.2%PRS 13.7%
-
CSI -0.9rCSI -1.1%PRS 11.1%
-
CSI -0.8rCSI -2.5%PRS 12.1%
-
CSI -0.6rCSI -3.4%PRS 4.7%
-
CSI -0.5rCSI -2.8%PRS 2.7%
-
CSI -0.4rCSI -1.0%PRS 4.7%
-
CSI -0.4rCSI -6.7%PRS 35.1%
-
CSI -0.1rCSI -0.4%PRS 5.1%
-
CSI -0.1rCSI -0.5%PRS 4.1%
-
CSI -0.1rCSI -0.2%PRS 4.3%
-
CSI 0.0rCSI 0.8%PRS 39.4%
-
CSI 0.0rCSI 0.1%PRS 4.8%
-
CSI 0.1rCSI 1.4%PRS 51.3%
-
CSI 0.1rCSI 0.1%PRS 4.9%
-
CSI 0.1rCSI 0.2%PRS 5.6%
-
CSI 0.1rCSI 1.6%PRS 74.6%
-
CSI 0.1rCSI 1.4%PRS 23.4%
-
CSI 0.1rCSI 0.9%PRS 24.8%
-
CSI 0.1rCSI 0.4%PRS 5.8%
-
CSI 0.2rCSI 1.0%PRS 11.5%
-
CSI 0.2rCSI 3.5%PRS 51.2%
-
CSI 0.2rCSI 4.7%PRS 26.1%
-
CSI 0.2rCSI 0.4%PRS 15.0%
-
CSI 0.2rCSI 0.7%PRS 11.8%
-
CSI 0.2rCSI 0.3%PRS 4.4%
-
CSI 0.2rCSI 0.9%PRS 38.6%
-
CSI 0.2rCSI 3.7%PRS 31.6%
-
CSI 0.2rCSI 5.2%PRS 3.1%
-
CSI 0.2rCSI 0.7%PRS 10.4%
-
CSI 0.2rCSI 5.0%PRS 43.8%
-
CSI 0.2rCSI 1.0%PRS 14.7%
-
CSI 0.2rCSI 2.4%PRS 22.6%
-
CSI 0.2rCSI 3.7%PRS 24.9%
-
CSI 0.3rCSI 0.6%PRS 5.4%
-
CSI 0.3rCSI 1.3%PRS 11.0%
-
CSI 0.3rCSI 2.3%PRS 33.1%
-
CSI 0.3rCSI 1.1%PRS 4.6%
-
CSI 0.3rCSI 2.1%PRS 15.0%
-
CSI 0.3rCSI 0.6%PRS 17.2%
-
CSI 0.3rCSI 1.3%PRS 16.2%
-
CSI 0.3rCSI 1.7%PRS 9.9%
-
CSI 0.3rCSI 1.5%PRS 16.2%
-
CSI 0.3rCSI 0.3%PRS 8.6%
-
CSI 0.3rCSI 8.1%PRS 3.9%
-
CSI 0.3rCSI 1.9%PRS 24.5%
-
CSI 0.4rCSI 1.0%PRS 14.8%
-
CSI 0.4rCSI 1.1%PRS 17.1%
-
CSI 0.4rCSI 1.8%PRS 20.7%
-
CSI 0.4rCSI 0.9%PRS 8.5%
-
CSI 0.4rCSI 2.7%PRS 25.7%
-
CSI 0.4rCSI 1.3%PRS 28.4%
-
CSI 0.4rCSI 1.1%PRS 12.9%
-
CSI 0.4rCSI 1.0%PRS 11.7%
-
CSI 0.5rCSI 1.1%PRS 9.9%
-
CSI 0.5rCSI 0.8%PRS 7.2%
-
CSI 0.5rCSI 2.0%PRS 33.3%
-
CSI 0.5rCSI 0.7%PRS 8.0%
-
CSI 0.5rCSI 0.6%PRS 10.6%
-
CSI 0.5rCSI 12.1%PRS 27.8%
-
CSI 0.5rCSI 1.4%PRS 12.9%
-
CSI 0.6rCSI 0.8%PRS 6.0%
-
CSI 0.6rCSI 0.8%PRS 7.1%
-
CSI 0.6rCSI 1.1%PRS 18.2%
-
CSI 0.6rCSI 1.1%PRS 9.4%
-
CSI 0.6rCSI 0.8%PRS 4.7%
-
CSI 0.6rCSI 1.2%PRS 2.9%
-
CSI 0.6rCSI 0.9%PRS 7.5%
-
CSI 0.6rCSI 2.9%PRS 18.5%
-
CSI 0.6rCSI 0.9%PRS 10.4%
-
CSI 0.6rCSI 1.8%PRS 10.9%
-
CSI 0.6rCSI 2.3%PRS 13.0%
-
CSI 0.7rCSI 2.1%PRS 8.6%
-
CSI 0.7rCSI 1.1%PRS 5.8%
-
CSI 0.7rCSI 7.7%PRS 30.8%
-
CSI 0.7rCSI 1.1%PRS 8.8%
-
CSI 0.7rCSI 1.8%PRS 8.3%
-
CSI 0.7rCSI 0.8%PRS 4.4%
-
CSI 0.7rCSI 3.0%PRS 13.9%
-
CSI 0.7rCSI 2.7%PRS 8.0%
-
CSI 0.8rCSI 1.2%PRS 9.8%
-
CSI 0.8rCSI 1.8%PRS 9.3%
-
CSI 0.8rCSI 5.6%PRS 21.1%
-
CSI 0.8rCSI 2.2%PRS 33.6%
-
CSI 0.8rCSI 3.2%PRS 16.7%
-
CSI 0.8rCSI 3.1%PRS 33.8%
-
CSI 0.9rCSI 2.2%PRS 23.2%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 825840430
Symbol: SF3B2_HUMAN
Name: Splicing factor 3B subunit 2
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 8566756
Title: Evidence that sequence-independent binding of highly conserved U2 snRNP proteins upstream of the branch site is required for assembly of spliceosomal complex A.
PubMed ID: 8566756
DOI: 10.1101/gad.10.2.233
PubMed ID: 10882114
Title: Functional association of U2 snRNP with the ATP-independent spliceosomal complex E.
PubMed ID: 10882114
PubMed ID: 12234937
Title: Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein.
PubMed ID: 12234937
DOI: 10.1093/emboj/cdf480
PubMed ID: 11991638
Title: Purification and characterization of native spliceosomes suitable for three-dimensional structural analysis.
PubMed ID: 11991638
PubMed ID: 12738865
Title: Molecular architecture of the multiprotein splicing factor SF3b.
PubMed ID: 12738865
PubMed ID: 15146077
Title: The human 18S U11/U12 snRNP contains a set of novel proteins not found in the U2-dependent spliceosome.
PubMed ID: 15146077
DOI: 10.1261/rna.7320604
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 16923959
Title: Human immunodeficiency virus type 1 Vpr induces G2 checkpoint activation by interacting with the splicing factor SAP145.
PubMed ID: 16923959
DOI: 10.1128/mcb.01170-06
PubMed ID: 17525332
Title: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
PubMed ID: 17525332
PubMed ID: 18691976
Title: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
PubMed ID: 18691976
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 18318008
Title: Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography.
PubMed ID: 18318008
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19690332
Title: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
PubMed ID: 19690332
PubMed ID: 19608861
Title: Lysine acetylation targets protein complexes and co-regulates major cellular functions.
PubMed ID: 19608861
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 21406692
Title: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
PubMed ID: 21406692
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 24129315
Title: Immunoaffinity enrichment and mass spectrometry analysis of protein methylation.
PubMed ID: 24129315
PubMed ID: 25218447
Title: Uncovering global SUMOylation signaling networks in a site-specific manner.
PubMed ID: 25218447
DOI: 10.1038/nsmb.2890
PubMed ID: 25772364
Title: SUMO-2 orchestrates chromatin modifiers in response to DNA damage.
PubMed ID: 25772364
PubMed ID: 25755297
Title: System-wide analysis of SUMOylation dynamics in response to replication stress reveals novel small ubiquitin-like modified target proteins and acceptor lysines relevant for genome stability.
PubMed ID: 25755297
PubMed ID: 28112733
Title: Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.
PubMed ID: 28112733
DOI: 10.1038/nsmb.3366
PubMed ID: 25737013
Title: PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145.
PubMed ID: 25737013
DOI: 10.1038/ncomms7428
PubMed ID: 25979344
Title: Unique features of human protein arginine methyltransferase 9 (PRMT9) and its substrate RNA splicing factor SF3B2.
PubMed ID: 25979344
PubMed ID: 26030138
Title: Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin Dynamics.
PubMed ID: 26030138
PubMed ID: 27720643
Title: Molecular architecture of SF3b and structural consequences of its cancer-related mutations.
PubMed ID: 27720643
PubMed ID: 27905398
Title: Structure of the RBM7-ZCCHC8 core of the NEXT complex reveals connections to splicing factors.
PubMed ID: 27905398
DOI: 10.1038/ncomms13573
PubMed ID: 28541300
Title: Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.
PubMed ID: 28541300
DOI: 10.1038/ncomms15522
PubMed ID: 32494006
Title: Molecular architecture of the human 17S U2 snRNP.
PubMed ID: 32494006
PubMed ID: 33509932
Title: Structure of the activated human minor spliceosome.
PubMed ID: 33509932
PubMed ID: 34822310
Title: Structural basis of branch site recognition by the human spliceosome.
PubMed ID: 34822310
PubMed ID: 36797247
Title: Mechanisms of the RNA helicases DDX42 and DDX46 in human U2 snRNP assembly.
PubMed ID: 36797247
PubMed ID: 34344887
Title: Haploinsufficiency of SF3B2 causes craniofacial microsomia.
PubMed ID: 34344887
Sequence Information:
- Length: 895
- Mass: 100228
- Checksum: D372AFA679443AD6
- Sequence:
MATEHPEPPK AELQLPPPPP PGHYGAWAAQ ELQAKLAEIG APIQGNREEL VERLQSYTRQ TGIVLNRPVL RGEDGDKAAP PPMSAQLPGI PMPPPPLGLP PLQPPPPPPP PPPGLGLGFP MAHPPNLGPP PPLRVGEPVA LSEEERLKLA QQQAALLMQQ EERAKQQGDH SLKEHELLEQ QKRAAVLLEQ ERQQEIAKMG TPVPRPPQDM GQIGVRTPLG PRVAAPVGPV GPTPTVLPMG APVPRPRGPP PPPGDENREM DDPSVGPKIP QALEKILQLK ESRQEEMNSQ QEEEEMETDA RSSLGQSASE TEEDTVSVSK KEKNRKRRNR KKKKKPQRVR GVSSESSGDR EKDSTRSRGS DSPAADVEIE YVTEEPEIYE PNFIFFKRIF EAFKLTDDVK KEKEKEPEKL DKLENSAAPK KKGFEEEHKD SDDDSSDDEQ EKKPEAPKLS KKKLRRMNRF TVAELKQLVA RPDVVEMHDV TAQDPKLLVH LKATRNSVPV PRHWCFKRKY LQGKRGIEKP PFELPDFIKR TGIQEMREAL QEKEEQKTMK SKMREKVRPK MGKIDIDYQK LHDAFFKWQT KPKLTIHGDL YYEGKEFETR LKEKKPGDLS DELRISLGMP VGPNAHKVPP PWLIAMQRYG PPPSYPNLKI PGLNSPIPES CSFGYHAGGW GKPPVDETGK PLYGDVFGTN AAEFQTKTEE EEIDRTPWGE LEPSDEESSE EEEEEESDED KPDETGFITP ADSGLITPGG FSSVPAGMET PELIELRKKK IEEAMDGSET PQLFTVLPEK RTATVGGAMM GSTHIYDMST VMSRKGPAPE LQGVEVALAP EELELDPMAM TQKYEEHVRE QQAQVEKEDF SDMVAEHAAK QKQKKRKAQP QDSRGGSKKY KEFKF